Cover Image
Market Research Report

Global Malaria Vaccines Market - 2019-2026

Published by DataM Intelligence Product code 803295
Published Content info 130-180 Pages
Delivery time: 1-2 business days
Back to Top
Global Malaria Vaccines Market - 2019-2026
Published: March 1, 2019 Content info: 130-180 Pages

Global Malaria Vaccines Market Overview

Malaria an intermittent and remittent fever caused by a protozoan parasite which invades the red blood cells and is transmitted by mosquitoes in many tropical and subtropical regions and leads to severe illness in both pediatrics and adults. The pregnant women and pediatrics are more frequently effected with malaria. It is also reported that malaria affected pregnant women give birth to premature baby or birth to dead infants. Malaria vaccines are considered amongst the most important modalities for prevention of malaria disease and reduction of malaria transmission. Researchers, clinical trialists and vaccine developers are focusing on developing on many approaches to bring forward the availability of vaccine. This vaccine helps in filling the gaps between various malaria safety measures.

The global malaria vaccines market was worth $XX billion in 2018 and is forecasted to reach $XX billion by 2026, at a CAGR of XX% during the forecast period.

Market Drivers:

The rapid surge in the incidence of malaria globally and majorly in the African region and an increase in funding by government organizations for the eradication of malaria in the sub-Saharan region is driving global vaccines market during the forecast period. R&D initiatives by research organizations for the development of pregnancy-related malaria vaccines and non-government organization funding for new vaccine development by research institutes and pilot programs in the sub-Saharan region are additionally driving the malaria vaccines market during the forecast period.

According to World Health Organisation in 2017, it is estimated that 3.4 billion people in 92 countries globally are at risk of being affected with malaria and developing disease out of which are 1.1 billion are at high risk.

According to WHO in 2017, the burden of malaria epidemiology is heaviest in the African region and estimated that 93% of malaria deaths occurred and in children aged five and below accounted to 61% of all deaths.

In January 2019, new pregnancy-associated malaria vaccine developed by University of Copenhagen passed first human trail.

In March 2018, Global Health innovative Technology Gund awarded the University of Florida and partners in the united states and Japan with $3.2 million to develop an advanced vaccine to prevent transmission of malaria.

Market Segmentation

Global malaria vaccines market is segmented by vaccine type, agent, and end users. Vaccine type includes pre-erythrocytic vaccines, blood-stage vaccine, and transmission blocking vaccines and agent type includes plasmodium falciparum and plasmodium vivax. End users include hospitals, clinics, vaccination centers, and community centers.

The pre-erythrocytic vaccines dominate the global malaria vaccines market during the forecast period owing to its extensive usage in vaccination programs due to its efficiency and the clinical advantages provided by vaccines it includes its inherent property of elimination the infections completely from the body and others.

Global Malaria Vaccines Market - Geographical Analysis

The global malaria vaccines market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa.

Middle East and Africa are dominating the global malaria vaccines market during the forecast period owing to rise in malaria across the emerging regions and various initiatives and funding by government and non-government organizations for eradicating malaria by awareness campaigns, cost-effective vaccine delivery and vaccination programs.

In April 2017, Gavi the vaccine alliance the global fund to Fight Aids, tuberculosis, and malaria and Unitraid are partnering to provide $49.2 million for the first phase of pilot programs. Ministries of health in Ghana, Kenya, and Malawi will implement the pilot program in coordination with WHO.

Global Malaria Vaccines Market - Competitive Analysis

New product launches and recent FDA approvals for initiating clinical trials of their novel technology vaccines by key players are driving the global malaria vaccines market during the forecast period.

On February 4th, 2019, VLP Therapeutics received U.S FDA clearance for initiating clinical trials of its new VLPM01 malaria vaccine.

In March 2018, researchers at Hyderabad based-center for molecular cellular and molecular biology started working on developing whole parasite vaccines that can be conditionally attenuated when given to humans.

In July 2015, the European medical agency committee for medical products for human use had adopted a scientific opinion for Mosquirix for use outside the European Union.

Major market players in the malaria vaccines market are VLP Therapeutics, GlaxoSmithKline Plc, Sanaria Inc., Mymetics Corporation, others.

Target Audience:

  • Equipment Suppliers/ Buyers
  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers
Table of Contents

Table of Contents


  • 1.1. Research Methodology
  • 1.2. The Scope of the market



  • 3.1. Drivers
  • 3.2. Restraints
  • 3.3. Opportunity
  • 3.4. Regulation
  • 3.5. Supply Chain Analysis
  • 3.6. Technological Advancements
  • 3.7. Porter's Five Forces Analysis


    • 4.1.1. Pre-Erythrocytic Vaccines
    • 4.1.2. Blood-Stage Vaccine
    • 4.1.3. Transmission-Blocking Vaccines
  • 4.2. BY AGENT
    • 4.2.1. Plasmodium Falciparum
    • 4.2.2. Plasmodium Vivax
  • 4.3. BY END USERS
    • 4.3.1. Hospitals
    • 4.3.2. Clinics
    • 4.3.3. Vaccination centers
    • 4.3.4. Community Centers


  • 5.1. Geographic Overview
  • 5.2. North America
    • 5.2.1. The U.S.
    • 5.2.2. Mexico
    • 5.2.3. Canada
  • 5.3. Europe
    • 5.3.1. Germany
    • 5.3.2. The U.K.
    • 5.3.3. France
    • 5.3.4. Italy
    • 5.3.5. Spain
    • 5.3.6. Rest of Europe
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
    • 5.4.3. Rest of South America
  • 5.5. Asia Pacific
    • 5.5.1. China
    • 5.5.2. India
    • 5.5.3. Japan
    • 5.5.4. Australia
    • 5.5.5. Rest of Asia Pacific
  • 5.6. Rest of World


  • 6.1. Competitive Scenario
  • 6.2. Heat Map Analysis
  • 6.3. Product Benchmarking


  • 7.1. VLP Therapeutics
  • 7.2. GlaxoSmithKline Plc
  • 7.3. Sanaria Inc.
  • 7.4. Mymetics Corporation
  • 7.5. Others

8. Key companies to watch

9. Emerging Companies


  • 10.1. Sources
  • 10.2. List of Tables
  • 10.3. Expert Panel Validation
  • 10.4. Disclaimer
  • 10.5. Contact Us
Back to Top